Pulmonary Disorders II

exacerbations of chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2006;(2):CD004403.

https://doi.org/10.1002/14651858.cd004403.pub2

Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic

glucocorticoids in severe exacerbations of COPD.

Chest.

2001;119(3):726-730.

https://doi.org/10.1378/

chest.119.3.726

Sivapalan P, Ingebrigtsen TS, Rasmussen DB, et al. COPD

exacerbations: the impact of long versus short courses of

oral corticosteroids on mortality and pneumonia: nation-

wide data on 67 000 patients with COPD followed for

12 months. BMJ Open Respir Res. 2019;6(1):e000407.

https://doi.org/10.1136/bmjresp-2019-000407

Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley

TS. Racial bias in pulse oximetry measurement. N Engl

J Med. 2020;383(25):2477-2478. https://doi.org/10.1056/

nejmc2029240

van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA.

Bronchodilators delivered by nebuliser versus pMDI

with spacer or DPI for exacerbations of COPD. Cochrane

Database Syst Rev. 2016;2016(8):CD011826. https://doi.

org/10.1002/14651858.cd011826.pub2

Vermeersch K, Gabrovska M, Aumann J, et al.

Azithromycin

during

acute

chronic

obstruc-

tive

pulmonary

disease

exacerbations

requiring

hospitalization (BACE). A multicenter, randomized,

rccm.201901-0094oc

Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-

Aymerich J, Puhan MA. Antibiotics for exacerbations

of chronic obstructive pulmonary disease. Cochrane

Database Syst Rev. 2018;10(10):CD010257. https://doi.

org/10.1002/14651858.cd010257.pub2

Wedzicha JA, Miravitlles M, Hurst JR, et al.

Management of COPD exacerbations: a European

Respiratory Society/American Thoracic Society guide-

line. Eur Respir J. 2017;49(3):1600791. https://doi.

org/10.1183/13993003.00791-2016